share_log

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

Vertex Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Bozic Carmen

福泰制药 | 4：持股变动声明-高管 Bozic Carmen
美股SEC公告 ·  08/08 16:10
Moomoo AI 已提取核心信息
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,280 shares of common stock on August 7, 2024. The transaction was executed at a price of $476.75 per share, resulting in a total sale value of $1,086,990. Following the sale, Bozic's direct holdings in the company amount to 23,259 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals.
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 2,280 shares of common stock on August 7, 2024. The transaction was executed at a price of $476.75 per share, resulting in a total sale value of $1,086,990. Following the sale, Bozic's direct holdings in the company amount to 23,259 shares. The sale took place in an open market transaction, as reported by Vertex Pharmaceuticals.
福泰制药（VRTX）的执行副总裁兼首席市场官Carmen Bozic于2024年8月7日完成了2,280股普通股的销售交易。交易价格为476.75美元每股，总销售价值为1,086,990美元。此次交易是在公开市场交易中完成的，Bozic在公司的直接持股总共有23,259股。据Vertex Pharmaceuticals报道。
福泰制药（VRTX）的执行副总裁兼首席市场官Carmen Bozic于2024年8月7日完成了2,280股普通股的销售交易。交易价格为476.75美元每股，总销售价值为1,086,990美元。此次交易是在公开市场交易中完成的，Bozic在公司的直接持股总共有23,259股。据Vertex Pharmaceuticals报道。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息